americanpharmaceuticalreviewSeptember 27, 2020
Tag: Algenex , Vaccine , facility
Algenex has opened its new facility in Tres Cantos, Spain. The new facility allows Algenex to produce up to 3.5kg of recombinant proteins, equivalent to around 100 million vaccine doses across animal and human health.
The facility comprises around 900m2 of rearing and production areas, molecular laboratories and office space. It also incorporates two small suites that will be dedicated to commercial manufacturing. The first suite will be dedicated to the manufacturing of Algenex’ Baculovirus-based proteins, while the second suite will be dedicated to the inoculation of the Trichoplusia ni pupae, which are used as natural bioreactors in the production of Algenex’ proteins. GMP certification for these two suites is targeted for Q1 2021.
The new facility took five months to complete and cost under EUR 2 million to build and is easily replicated to scale up production as required. This is in contrast to traditional bioreactor facilities, which require substantial capital expenditure and take two to three years to put in place.
“We are pleased to inaugurate our new facility, which enables Algenex to significantly increase its capacity to provide protein production solutions to the healthcare industry across both animal and human health applications,” said Claudia Jiménez, CEO of Algenex. “The global COVID-19 pandemic has highlighted the urgent need for the rapid production of large quantities of vaccine at an affordable cost and Algenex is ready to put its technology and expertise to work to provide an efficient, scalable and cost-effective manufacturing option that allows the implementation of timely and global vaccination campaigns.”
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: